Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

Regenersis plc (RGS)     

dreamcatcher - 26 Sep 2012 20:57




We help our clients and their customers successfully deploy,
protect, maintain, retire and re-use technology.


The world is witnessing explosive growth in the number of connected devices, and in the power and complexity of mobile computing platforms. This is resulting in an increasing need for sophisticated technology- and user support. Regenersis addresses those needs with a growing portfolio of software-rich services building on a strong heritage of repair operations, customer service and data erasure management.

By combining our capabilities in innovative ways, tailored to individual client requirements, we deliver unique service propositions that reinforce trust in our client’s brands and create value for our business partners and shareholders.


Technology Life Cycle Services

Our international network of repair centres provides product repair, refurbishment, parts management and logistics services for mobile, IT, home entertainment and B2B infrastructure product vendors; and their sales channels, insurers, and end users. Our technically-advanced repair capabilities enjoy a solid reputation with our TMT sector clients, combining service excellence with continuous gains in cost efficiency.

Our industry-leading fault diagnostics and issue resolution technologies include the In-Field Tester for set top boxes, and our SmartChk applications suite for smartphones. These advanced diagnostic platforms improve consumer satisfaction with their devices and materially reduce the incidence and cost of product returns for our clients.

In partnership with leading insurers, our Digital Care operations deliver innovative product insurance and extended warranty programmes for our clients, protecting customers’ investments in mobile technology products.

Our Recommerce division helps manufacturers and retailers to launch products and attract new customers through upgrade and buy-back programmes.

Blancco is the global leader in data erasure management (DEM). Blancco software provides comprehensive data erasure for every type of electronic and magnetic storage media, ranging from portable flash drives and mobile phone memory to solid state drives, networked storage, virtual drives and cloud storage. Blancco DEM is a vital part of any organisation’s security infrastructure, underpinning robust data retention policies and ensuring compliance with international data protection regulations.

Regenersis around the world

Our clients increasingly seek partners who can deliver cost-effective and innovative technology life cycle services on a global basis. Since 2011, Regenersis has expanded its geographical footprint from five countries to 16. With the acquisition of Blancco in April 2014, this increased to 22 countries.



http://www.regenersis.com/about-us



Chart.aspx?Provider=EODIntra&Code=RGS&SiChart.aspx?Provider=EODIntra&Code=RGS&Si




Final Results

http://www.moneyam.com/action/news/showArticle?id=4451090

Financial Highlights

·
Group revenue increased by 13% to £139.9 million (2011: £123.8 million)

·
Headline operating profit(*) increased by 24% to £7.8 million (2011: £6.3 million)

·
Operating cash flow improved to £4.9 million (2011: £2.4 million).

·
Further Improvement in headline operating margin to 5.5% (2011: 5.1%)

·
Net debt reduced to £2.9 million (2011: £3.8 million)

·
Banking facility extended from £15 million to £23.25 million for the period to October 2015, to support further organic investment and incremental M&A activity

·
First dividend payment since 2007 - recommended final dividend of 1.1 pence per ordinary share

dreamcatcher - 19 Oct 2015 17:45 - 178 of 183

A strong recovery.

Bullshare - 25 Nov 2015 14:14 - 179 of 183

Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.

Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutions
Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Tuesday 15th December 2015

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Andrew Newland, CEO - Angle (AGL)
• Jog Dhody, CFO - Regenersis (RGS)
• Dr. Satu Vainikka, CEO - Valirx (VAL)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Angle (AGL)
Angle (AGL) 

ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

 

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

 

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

·         Early detection of cancer;

·         Personalised cancer treatment;

·         Monitoring of cancer patients during treatment; and

·         Post-treatment monitoring of cancer patients in remission.

Regenersis (RGS)
Regenersis (RGS) 

Regenersis is a leading, strategic outsourcing partner to the world’s premier consumer technology brands. Regenersis has built an increasingly global network of repair centres, delivered double digit revenue and profit growth, through cross-sell related services to major OEMs and network operators. In addition, the Group has traction with its scalable, high margin Advanced Solutions offering across the mobile and set top box markets.

Valirx (VAL)
Valirx (VAL) 

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Sponsored by:
AJ Bell Youinvest
London Stock Exchange

cp1 - 13 Jan 2016 08:50 - 180 of 183

This may well be worth another look with sterling coming off against the euro and falling significantly against the U.S dollar.

Once they sell the after service business then we are looking at a very fast growing pure software business. Certainly could fly if it can recapture 250p area and the sale goes to plan as this morning's rns seems to suggest.

cp1 - 08 Mar 2016 07:56 - 181 of 183

Excellent news. Now the pound isn't killing them, these look to have a very exciting growth business with Blancco. Should start to be re-rated very soon.

cp1 - 08 Mar 2016 09:25 - 182 of 183

Panmure BUY note 320p target.

cp1 - 15 Mar 2016 11:05 - 183 of 183

re-rating afoot....

Been over £4 last year and as I've stated before, the weak pound is very good for this one. Lots of upside to come here folks.
Register now or login to post to this thread.